USPTO serial 79353523
BIONTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 19, 2023
- Examiner
- REGAN, JOHN B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIONTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in pharmaceutical industry; active chemical ingredients for use in manufacture of anti-cancer drugs and vaccines; adjuvants for use in manufacture of vaccines; nucleic acids, proteins and peptides for laboratory use; diagnostic preparations for scientific or research use other than for medical purposes | ACTIVE | — |
| 005 | Pharmaceutical products for the prevention and treatment of cancer, infectious diseases, and immunological diseases, except vitamin preparations, mineral food supplements, probiotics, omega 3 preparations, dietetic substances and food supplements for medical and non-medical purposes; Vaccines; Chemical reagents used for medical purposes; Biochemical reagents used for purposes for the treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; Macromolecules, namely, nucleic acid sequences and proteins, used for medical and veterinary purposes; cell based immune therapeutics for treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; diagnostic preparations for clinical or medical laboratory use | ACTIVE | — |
| 009 | Downloadable mobile applications for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable computer software for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable e-commerce computer software for enabling users to perform electronic business transactions via a global computer network | ACTIVE | — |
| 010 | Medical diagnostic devices for analysis of body fluids and biopsies for diagnosis and monitoring of cancer, infectious diseases, and immunological diseases; medical diagnostic devices for analysis of body fluids and biopsies for patient stratification | ACTIVE | — |
| 035 | Business advisory services in the field of electronic commerce; providing business information in the field of electronic commerce; providing business information, namely, customer information on pharmaceutical and medical products through an on-line computer network; wholesale and retail store services featuring pharmaceutical products, medicinal preparations, and medical supplies | ACTIVE | — |
| 042 | medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; medical and scientific research services by compiling data for clinical trials and drug admission | ACTIVE | — |
| 044 | Medical, hygienic and beauty care; healthcare services; provision of medical information and services; provision of medical information to patients and healthcare professionals concerning pharmaceutical products, vaccines, medical products, medical diseases and disorders and related treatments via the Internet; medical services in the field of gene therapy; medical services in the field of cell therapy; medical and health care services; medical services, namely, providing therapies for treating cancer, infectious diseases and immunological diseases; veterinary services, namely, providing therapies for treating cancer, infectious diseases, and immunological diseases; medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioNTech SE
- Other trademarks owned by BioNTech SE
- Other trademarks owned by BioNTech SE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BIONTECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 31, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 26, 2024 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jun 17, 2024 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jan 8, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 21, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 21, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 19, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 25, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 25, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 25, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 19, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 19, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 11, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 4, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 4, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 21, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 14, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 26, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 3, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 3, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 31, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 15, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 20, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 20, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 15, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 14, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 11, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 7, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 1, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 27, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |